This improvement aligns with clinical trial results, such as those from the CLEOPATRA trial, which showed the survival benefits of combining HER2-targeted therapies with chemotherapy for metastatic HER2-positive breast cancer [5]. The gene discussed is ERBB2; the disease is breast carcinoma.